UroGen Pharma’s (URGN) “Buy” Rating Reaffirmed at D. Boral Capital

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reaffirmed by equities research analysts at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They presently have a $25.00 price target on the stock. D. Boral Capital’s price target points to a potential upside of 148.76% from the stock’s current price.

A number of other research firms also recently issued reports on URGN. EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. Oppenheimer restated an “outperform” rating and issued a $40.00 target price on shares of UroGen Pharma in a report on Wednesday, October 16th. Finally, HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of UroGen Pharma in a report on Tuesday, October 15th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $43.70.

UroGen Pharma Stock Performance

NASDAQ:URGN opened at $10.05 on Thursday. The firm has a 50 day simple moving average of $11.30 and a 200-day simple moving average of $13.03. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The firm has a market cap of $235.67 million, a PE ratio of -3.19 and a beta of 1.09. UroGen Pharma has a 1-year low of $9.78 and a 1-year high of $20.70.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.29. The firm had revenue of $25.20 million during the quarter, compared to analyst estimates of $24.22 million. During the same period in the prior year, the firm earned ($0.68) EPS. On average, equities analysts expect that UroGen Pharma will post -3.1 EPS for the current year.

Institutional Investors Weigh In On UroGen Pharma

Several institutional investors have recently bought and sold shares of URGN. China Universal Asset Management Co. Ltd. grew its stake in UroGen Pharma by 90.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock worth $103,000 after buying an additional 3,856 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of UroGen Pharma by 221.8% in the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after purchasing an additional 5,890 shares during the period. Intech Investment Management LLC purchased a new position in shares of UroGen Pharma in the third quarter valued at $155,000. Verition Fund Management LLC purchased a new position in shares of UroGen Pharma in the third quarter valued at $168,000. Finally, SG Americas Securities LLC purchased a new position in shares of UroGen Pharma in the third quarter valued at $179,000. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.